Humana (OM:HUM) has just posted its Q2 2026 numbers, with revenue at SEK2.6 billion, basic EPS at a loss of SEK0.19 and net income excluding extra items at a loss of SEK9 million. Over the past six quarters, the company has seen quarterly revenue range between SEK2.5 billion and SEK2.6 billion. Basic EPS moved from SEK0.36 in Q2 2025 to SEK2.42 in Q3 2025, then SEK1.44 in Q1 2025 and SEK0.79 in Q1 2026, before this quarter’s loss. For investors, the latest print puts the focus squarely on how sustainably Humana can convert its revenue base into profit as margins come under closer scrutiny.

See our full analysis for Humana.

With the headline figures on the table, the next step is to compare these results with the most common Humana narratives to see which storylines the latest margins and earnings support and which they push back against.

See what the community is saying about Humana

Margins Under Pressure Despite SEK10.0b LTM Revenue

• On a trailing 12 month basis, Humana generated about SEK10.0b in revenue and SEK173 million in net income excluding extra items, which works out to a 1.7% net margin compared with 2.1% a year earlier in the dataset.
• What stands out against the bullish narrative of higher future margins is that recent profitability is still quite thin, even though bulls expect margins to rise from around 2.0% to 3.8%, and:
  • Trailing 12 month EPS sits at SEK3.57 while the latest quarter showed a loss of SEK0.19 per share. The recent softness therefore contrasts with the steadily positive trailing figure.
  • Bulls point to SEK100 million of identified cost savings and efficiency programs. However, the reported 1.7% margin and the Q2 2026 net loss of SEK9 million indicate that these benefits are not fully visible in the latest quarterly snapshot.

On these numbers, some investors may want to see how bullish analysts reconcile thin current margins with their more optimistic long term view of Humana. 🐂 Humana Bull Case

Humana’s Valuation Gap Versus SEK68.50 Target

• The stock trades at SEK62.70 with a P/E of 17.2x, which sits below both the European healthcare industry average of 20.5x and a peer average of 22.9x, while the DCF fair value in the dataset is SEK228.94.
• Consensus narrative suggests the current price leaves room compared with a SEK68.50 analyst target and higher DCF fair value, yet the earnings profile is mixed, because:
  • Reported earnings over the last year include a SEK48 million one off gain, so part of the trailing profit that feeds into the P/E and DCF inputs is not from recurring operations.
  • Net margin over the last 12 months is 1.7%, down from 2.1% in the prior period cited, so the relatively low P/E and large gap to DCF fair value sit alongside a modest profitability base.

Bears Focus On Thin 1.7% Margin And One Offs

• Bears highlight that earnings have declined at about 7.6% a year over five years, while the latest trailing net margin is 1.7% and includes that SEK48 million one off gain, which inflates underlying profitability.
• This set of figures gives the cautious narrative some backing, yet also shows where it can be tested, because:
  • Over the last four trailing 12 month periods in the dataset, revenue has stayed close to SEK10.0b while net income excluding extra items ranged between SEK173 million and SEK240 million. Profitability has therefore been positive even if not high.
  • The current price of SEK62.70 sits below the SEK68.50 analyst target, so while bears point to low margins and one off support for earnings, the market price already reflects some of those concerns relative to that target.

Skeptical investors who focus on the slim margin and one off gain may want to see how that caution stacks up against the detailed bearish case for Humana. 🐻 Humana Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Humana on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Reading these mixed signals around Humana’s margins and valuation, it makes sense to look at the underlying data yourself and move quickly to form a clear opinion. To get a concise view of both sides of the story, start by reviewing the 3 key rewards and 3 important warning signs.

See What Else Is Out There

Humana is operating with thin 1.7% net margins, a recent quarterly loss and some earnings support from one off items, which all raise quality questions.

If you want ideas where profitability appears more robust and pricing may already reflect stronger fundamentals, check out the 226 high quality undervalued stocks for opportunities that could better align with your return goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.